NewAmsterdam Pharma Company N.V. (NAMS)
NAMS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/0001193125-26-056029-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NAMS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Netherlands |
| IPO year | Not reported by the screener |
| SEC CIK | 0001936258 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Netherlands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $22.5M |
| Net income | -$203.8M |
| Operating income | -$225.7M |
| Net margin | -905.7% |
| Operating margin | -1002.9% |
| Revenue growth | -50.6% |
| Cash | $490.0M |
| Total assets | $769.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 103.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $423.1M cash; operating cash flow -$37.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 119,929,998 (2026-11-02); 113,390,804 a year earlier; 89,266,673 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte Accountants B.V., Eindhoven, Netherlands | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $227K, sold $62.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $19.2M | -$17.4M | -$39.8M | $423.1M | No debt tags | $25.9M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $3.7M | -$64.1M | -$39.2M | $424.2M | No debt tags | $7.1M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $3.0M | -$48.4M | -$30.6M | $457.6M | No debt tags | $22.6M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $32K | -$74.9M | -$40.9M | $490.0M | No debt tags | $22.5M | 10-K 2026-02-18 |
| Q3 2025 2025-09-30 | $348K | -$72.0M | -$32.8M | $538.4M | No debt tags | $35.2M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $19.1M | -$17.4M | -$37.7M | $563.9M | No debt tags | $64.0M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $3.0M | -$39.5M | -$36.5M | $748.4M | No debt tags | $47.1M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $12.8M | -$92.2M | -$37.5M | $771.7M | No debt tags | $45.6M | 10-K 2026-02-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-03-10 |
| Latest annual report | 10-K | 2026-02-18 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEF 14A | 2026-05-06 |
Source: SEC EDGAR submissions feed, 417 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.6% |
| 1 month | -0.2% |
| 3 months | -24.5% |
| Year to date | -42.6% |
| 1 year | -44.7% |
| From 52-week high | -51.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| NAMSW | NewAmsterdam Pharma Company N.V. Warrant | $9.49 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LKFT | Lakefront Biotherapeutics | $34.79 | +2.38% | $2.3B |
| PBH | Prestige Consumer Healthcare Inc. | $48.00 | +3.92% | $2.3B |
| PHVS | Pharvaris N.V. | $32.44 | -2.76% | $2.3B |
| PRGO | Perrigo Company plc | $16.18 | -0.37% | $2.2B |
| RCUS | Arcus Biosciences Inc. | $16.86 | -3.27% | $2.4B |
| HCM | HUTCHMED (China) Limited | $14.73 | -1.14% | $2.6B |
| PVLA | Palvella Therapeutics Inc. | $144.60 | -5.17% | $2.1B |
| BHVN | Biohaven Ltd. Common Shares | $13.80 | -0.14% | $2.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier